ArticleFrontiers in endocrinology2025
A Nomogram for Predicting Lung Metastasis in Papillary Thyroid Cancer Patients Aged Less Than 55 Years.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Highlights: A nomogram predicting lung metastasis in patients with papillary thyroid cancer was developed and validated. Our study focused on patients under 55 years old, revealing the genetic factors linked to lung metastasis in this younger group. Young patients with the BRAF V600E mutation are less likely to develop lung metastasis. Objective: To develop and validate a nomogram for predicting the risk of lung metastasis in patients under 55 years old with papillary thyroid cancer (PTC). Methods: A total of 243 patients under 55 years old with PTC were retrospectively collected from January 2017 to June 2020 and randomly divided into a training group (n = 170) and a validation group (n = 73) in a 7:3 ratio. Genetic testing data and clinical information were compiled, and univariate and multivariate binary logistic regression analyses were performed. Based on the results, a nomogram predicting the risk of lung metastasis was constructed using the training cohort. The nomogram's performance was assessed using calibration curves, decision curve analysis (DCA), the concordance index (C-index), and the area under the receiver operating characteristic (ROC) curve (AUC) in both the training and validation groups. Results: T stage, unilateral thyroid involvement, TERT mutation, and BRAF mutation were identified as independent prognostic factors and were used to construct the nomogram. The C-index of the model was 0.89 in the training group and 0.88 in the validation group. The AUC, DCA, and calibration curves demonstrated favorable predictive accuracy. Using a cut-off value of 0.229, the nomogram achieved a sensitivity of 0.829 and a specificity of 0.793. Conclusion: A nomogram with strong predictive performance has been successfully developed and validated, which may assist clinicians in estimating the risk of lung metastasis in young patients with PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.